Ineffectiveness of adenine arabinoside and adenine arabinoside 5'-monophosphate in simian varicella infection.
Adenine arabinoside and adenine arabinoside 5'-monophosphate (ara-AMP) have been evaluated for antiviral activity against simian varicella virus infection in monkeys. In a preliminary study for toxicity, intramuscular injection of ara-AMP at 15 mg/kg per day as a single injection for 5 days to two normal patas monkeys caused no detectable local reaction, no weight loss or changes in serum transaminase levels, and no hematological abnormalities. When this dose was given in the treatment of four simian varicella virus-infected patas monkeys, no effect was observed on the clinical course of infection, as compared with four infected monkeys which received phosphate-buffered saline. Treatment was begun 43 h after virus inoculation and was continued for 16 days. Toxicity of intravenously administered ara-AMP at 100 to 50 mg/kg per day for 5 days to pairs of uninfected patas monkeys was evident by hematological and hepatic histological alterations, as well as the death of one monkey in each pair. No gross evidence of toxicity occurred in two monkeys which received 20 mg of ara-AMP per kg per day. The antiviral efficacy of intravenous treatment was studied in groups of four African green monkeys which received adenine arabinoside at 15 mg/kg per day or ara-AMP at 18.4 mg/kg per day. Drug administration began 48 h after inoculation with simian varicella virus and continued for 10 days. The monkeys that received treatment did not respond to infection differently from four infected control monkeys similarly treated with phosphate-buffered saline.
D000818:Animals; D001088:Arabinonucleotides / Q000627:therapeutic use*; D002644:Chickenpox / Q000188:drug therapy*; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D004901:Erythrocebus patas; D005260:Female; D000882:Haplorhini; D014645:Herpesvirus 3, Human / Q000187:drug effects; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D014740:Vidarabine / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D001084:Vidarabine Phosphate / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity
D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; D000637:Transaminases; D014740:Vidarabine